Objective. To investigate liver enzyme abnormalities and hepatic adverse events (AEs) during long-term tocilizumab treatment for rheumatoid arthritis in clinical trials.
Objective. To investigate liver enzyme abnormalities and hepatic adverse events (AEs) during long-term tocilizumab treatment for rheumatoid arthritis in clinical trials.
Methods. Data were pooled from patients who received intravenous tocilizumab (4, 8, or 10 mg/kg with or without disease-modifying antirheumatic drugs [DMARDs]) in phase III or IV clinical trials, long-term extensions, and a pharmacology study. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels were measured routinely in these trials. AE rates were measured per 100 patient-years of tocilizumab exposure for this pooled analysis.
Results. Overall, 16,204.8 patient-years of tocilizumab exposure (mean 6 SD duration of exposure 3.9 6 2.0 years) were evaluated for 4,171 patients. ALT and AST elevations greater than the upper limit of normal (ULN) occurred in 70.6% and 59.4% of patients, respectively. ALT/AST elevations were >1-33 ULN in 59%/55% of patients, >3-53 ULN in 8.9%/3.3% of patients, and >53 ULN in 2.9%/0.9% of patients. Most elevations occurred during the first year of treatment. Single ALT/AST elevations >33 ULN occurred in 7.7%/3.6% of patients, and ‡2 consecutive elevations >33 ULN occurred in 1.9%/0.4% of patients. Elevations >33 ULN returned to normal in 80% of patients (median of 5.6 weeks to normalization). A total of 2.5% of patients withdrew from tocilizumab treatment following ALT/AST elevations. A total of 7 hepatic serious AEs (SAEs) (0.04 per 100 patient-years [95% confidence interval 0.02-0.09]) occurred in the tocilizumab studies.
Conclusion. Transaminase elevations with tocilizumab were frequent, but rates of hepatic SAEs were low in this clinical trial data set. Regular monitoring, with dose adjustment of tocilizumab/DMARDs for persistent elevations, is recommended.
The proinflammatory cytokine interleukin-6 (IL-6) is a central mediator of the systemic and synovial inflammation that leads to erosion of bone and cartilage and to progressive joint damage in rheumatoid arthritis (RA) (1, 2) . In human hepatocytes, IL-6, IL-1, tumor necrosis factor (TNF), and other cytokines regulate the synthesis of acute-phase proteins during inflammation (3, 4) . IL-6 was identified as the stimulatory factor responsible for the induction of the acute-phase response in cultured human hepatocytes (5) , and recombinant human IL-6 induced the synthesis of a number of acute-phase proteins in human hepatocytes, the most strongly induced of which were serum amyloid A (SAA) and C-reactive protein (CRP) (6) . Furthermore, IL-6, but not IL-1 or TNF, regulates CRP synthesis at the transcriptional level (7) , and animal studies demonstrated that IL-6 may play a role in hepatocyte proliferation and fibrosis (8, 9) . Transgenic mice lacking endogenous IL-6 have a reduced acute-phase response to tissue injury (e.g., decreased SAA levels), indicating that IL-6 is important for the induction of the acutephase response in vivo (9) (10) (11) . IL-6-deficient mice exhibit signs of liver failure and impaired hepatocyte regeneration (8, 12) .
Tocilizumab is a recombinant, humanized, monoclonal antibody that binds to soluble and membranebound IL-6 receptor a and inhibits IL-6 signaling pathways (13, 14) . It has been shown in clinical trials to improve the signs and symptoms of RA and to reduce joint damage (15) (16) (17) (18) (19) (20) .
Tocilizumab treatment is associated with elevations in serum liver enzyme levels (21) . Clinical consequences of these laboratory elevations have not been evident in clinical trials or clinical practice to date. The potential impact of changes in transaminase levels is particularly relevant in RA patients who are also receiving methotrexate (MTX) or other concomitant medications that are known to affect liver enzyme levels. To characterize liver enzyme abnormalities in more detail than is found in initial reports from tocilizumab clinical trials and to assess any potential associations with serious adverse events (SAEs) of the liver over a longer treatment period, laboratory and safety data were pooled from a large RA clinical trial program. Results of these pooled analyses are presented herein.
PATIENTS AND METHODS
Patient populations. All-exposure population. The all-exposure population included all patients who received $1 dose of tocilizumab at 4 mg/kg, 8 mg/kg, or 10 mg/kg and who had $1 postbaseline safety assessment in any of the 5 core phase III placebo-controlled studies (15) (16) (17) (18) (19) , a clinical pharmacology study (22, 23) , a phase IV study (20) , or long-term extension studies. Original data sets were pooled and analyzed from each patient's initial tocilizumab exposure to May 2, 2012, by which time most patients had completed the studies. Patients in the phase III placebo-controlled studies were randomly assigned to receive 8 mg/kg tocilizumab with or without disease-modifying antirheumatic drugs (DMARDs), 4 mg/kg tocilizumab plus DMARDs, or placebo plus DMARDs every 4 weeks. Patients in the long-term extension studies received open-label tocilizumab at 8 mg/kg with or without DMARDs. Tocilizumab and placebo treatments were given to patients intravenously. Investigators were permitted to modify the dose of tocilizumab (e.g., temporarily reduce the dose to 4 mg/kg or skip doses entirely) as clinically required for safety reasons according to the clinical trial protocols. Patients in the phase IV study received 8 mg/kg tocilizumab intravenously every 4 weeks or 40 mg/kg adalimumab subcutaneously every 2 weeks. Patients in the clinical pharmacology study received a single intravenous dose (10 mg/kg) of tocilizumab.
Placebo-controlled population. This population included patients who received $1 dose of tocilizumab at 4 mg/kg or 8 mg/ kg during the double-blind treatment phase of the 5 phase III placebo-controlled studies; placebo data were also analyzed. Data were pooled for the population of patients with an inadequate response to DMARDs (15, 17, 19) and are presented for the population of patients with an inadequate response to anti-TNF (16) and for patients who were MTX-naive or who had not received MTX in the past 6 months (6-month MTX-free patients) (18) . Data were included from randomization until the first change in treatment (on initiation of rescue therapy or entry into an open-label extension phase) or until a duration of 1 year was reached in the radiographic study in patients with an inadequate response to DMARDs (19) .
Monotherapy populations. To assess events occurring with tocilizumab monotherapy, patients treated with tocilizumab monotherapy at 8 mg/kg were included from 3 different studies. Patients in the double-blind, active-controlled, phase IV study received tocilizumab monotherapy at 8 mg/kg; per study entry criteria, these patients had a history of intolerance to MTX or the study investigator considered MTX inappropriate for their treatment (20) . Patients in the doubleblind, placebo-controlled study that included an MTX-naive or a 6-month MTX-free population received tocilizumab monotherapy at 8 mg/kg; these patients were either MTXnaive or non-MTX-naive, and MTX treatment had not previously failed for them or they had received it within 6 months before study entry (18) . Patients in the double-blind, placebo-controlled 2-year study in early RA (24) received tocilizumab monotherapy at 8 mg/kg; these patients were MTX-naive and had had RA for #2 years. Data for the first 52 weeks of treatment in this study are included. Data from the 4 mg/kg tocilizumab plus MTX and the 8 mg/kg tocilizumab plus MTX treatment arms in this study were pooled to evaluate combination therapy. Data from patients in the placebo plus MTX arm were also analyzed (24) .
In all trials, patients were excluded from entering the study if they had alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels .1.53 the upper limit of normal (ULN) at screening. Patients with known active current or history of recurrent hepatitis B and C, history of alcohol or chemical abuse during the 6 months before screening, evidence of serious uncontrolled concomitant hepatic disease, or current hepatic disease as determined by the principal investigator were also excluded from the clinical trials.
Analyses. AE classification. In the current analysis, AEs and SAEs were coded using the Medical Dictionary for Regulatory Activities (MedDRA) version 15 Exposure to tocilizumab. Baseline was defined as the day of the first tocilizumab infusion in one of the clinical trials or extension studies. AE rates were calculated as the total number of AEs divided by the total patient-years of exposure to study treatment and were expressed per 100 patientyears with a 95% confidence interval (95% CI). Multiple occurrences of the same AE in a patient were counted. Patient-year exposure was based on the study duration for each patient and was calculated as the date of the last safety observation minus the date of the first tocilizumab dose plus 1; total patient-year exposure was the cumulative duration for all patients in the studies. Results are provided in the form of summary statistics and were calculated based on all available nonmissing data. Percentages are based on counts as a proportion of the total number of patients assessed within a category.
ALT/AST monitoring. ALT and AST levels were measured at baseline, every 2 weeks until week 16 (except week 10), and then every 4 weeks in the 5 phase III double-blind studies and every 12 weeks in the extension studies until the cutoff date. In the phase IV study, ALT/AST levels were measured at baseline and every 2 weeks throughout the study. In the early RA study, ALT/AST levels were measured every 4 weeks during the first 28 weeks of the study and every 8 weeks thereafter until the end of the reporting period at week 52.
Laboratory measurements were taken immediately before tocilizumab infusion, and investigators were unaware of the results at the time of infusion. DMARD and tocilizumab doses were to be modified for ALT/AST elevations. Recommendations in the protocols were the same as or similar to those in the US prescribing information and in the European Medicines Agency Summary of Product Characteristics for tocilizumab (25, 26) . In patients with ALT/AST levels .1-33 ULN at $2 consecutive visits, concomitant DMARDs were to be interrupted; this was followed by dose reduction or interruption of tocilizumab if the elevation persisted. In patients with ALT/AST levels .3-53 ULN at $2 consecutive visits, tocilizumab was to be interrupted until the level decreased to ,33 ULN. In patients with a single ALT/AST measurement .53 ULN or with persistent measurements $33 ULN, tocilizumab was to be permanently discontinued. Patients withdrawn from the study because of elevated ALT/AST levels were followed up until levels returned to baseline. If levels did not return to baseline within 6 months (or sooner if deemed necessary by the investigator), ultrasound or liver biopsy, or both, was recommended but not required.
To evaluate patients who could be at increased risk of drug-induced liver injury according to Hy's law (ALT or AST levels .33 ULN plus bilirubin level .23 ULN, no evidence of cholestasis [i.e., serum alkaline phosphatase not .23 ULN] (27) , and no other explanation such as viral hepatitis, preexisting or acute liver disease, or another drug capable of causing the observed injury), all instances of a .33 ULN ALT or AST elevation concurrent with a .23 ULN total bilirubin elevation were adjudicated by an independent hepatology consultant.
RESULTS
Patient populations and exposure. Findings in the all-exposure population. A total of 4,171 patients were included in the all-exposure population. The mean 6 SD duration of exposure to tocilizumab was 3.9 6 2.0 years (median 5.1 years); total exposure to tocilizumab was 16,204.8 patient-years. The all-exposure population comprised patients with moderate-to-severe RA from a variety of patient populations (including those with an inadequate response to DMARDs, those with an inadequate response to anti-TNF, and those who were MTX-naive). Baseline demographics and disease characteristics were consistent with those typical for patients with moderate-to-severe RA in clinical trials (see Supplementary Table 2 , http://onlinelibrary.wiley. com/doi/10.1002/art.40176/abstract). Most patients were women (81.9%) and white (74.7%); the mean age of patients was 52.1 years (range 18-89 years). Most patients (76%) were receiving concomitant MTX at baseline, and 3.6% received leflunomide. The mean 6 SD MTX dosage at baseline was 15.2 6 5.96 mg/week; midway through the study period, at week 156, the mean MTX dosage was 15.3 mg/week.
Findings in the placebo-controlled population. During placebo-controlled periods, 2,644 patients received tocilizumab (1,560 patient-years of exposure), and 1,454 patients received placebo plus MTX/DMARDs (743 patient-years of exposure).
Findings in the monotherapy populations. In the phase IV study, 162 patients received tocilizumab monotherapy at 8 mg/kg, providing a total of 68.5 patient-years of exposure over 24 weeks. In the study in MTX-naive and 6-month MTX-free patients, 288 patients received tocilizumab monotherapy at 8 mg/kg, providing a total exposure of 125.6 patient-years over 24 weeks. In the early RA study, 292 patients received tocilizumab monotherapy at 8 mg/kg, providing a total of 260.6 patient-years of exposure through week 52.
Patterns of ALT/AST elevations. In the allexposure population, 92.2% and 95.2% of patients, respectively, had ALT and AST levels within the normal range at the baseline visit before receiving their first dose of tocilizumab. Mean 6 SD ALT/AST levels increased from baseline within the normal range by 18 6 32 units/liter for ALT and by 8 6 15 units/liter for AST within 2 weeks after tocilizumab initiation and remained stable at the higher levels thereafter. ALT and AST levels increased from normal at baseline to .ULN at least once during the study period in 70.6% of patients (2, Patterns of ALT/AST elevations were also evaluated over time. In the all-exposure population, analysis of ALT and AST elevations .1-23 ULN, .2-33 ULN, .3-53 ULN, and .53 ULN over 12-month periods showed that the proportion of patients with elevations was highest during the first 12 months, and there was no evidence of increased risk of elevations over time. During the first year, ALT/AST elevations .1-33 ULN, .3-53 ULN, and .53 ULN occurred in 49.9%/41.8%, 5.8%/1.8%, and 1.5%/0.4% of patients, respectively; during months 73-84, the proportions were 23.5%/13.0%, 0.7%/0.4%, and 0.2%/0.3%, respectively ( Figure 2 ). Patients with ALT/AST elevations .ULN during the first 12 months of tocilizumab treatment were more likely to have subsequent elevations to .13 ULN and .33 ULN during each subsequent 12-month period analyzed compared with patients with ALT/AST #13 ULN during the first 12 months. Patients with ALT/AST values within the reference range for the first 12 months of tocilizumab treatment had a 24.0% incidence of ALT/AST elevations to .13 ULN and a 0.6% incidence of ALT/AST elevations to .33 ULN in the subsequent 12-month period (13-24 months) compared with incidences of 63.9% and 5.4%, respectively, for patients who had $1 occurrence of ALT/AST .ULN during the first 12 months of tocilizumab treatment.
Evaluation of patterns of ALT/AST increases during the analysis period showed that single occurrences of ALT/AST elevations .1-33 ULN were reported in 12.2% of patients for ALT and in 15.8% of patients for AST. For ALT, consecutive elevations were reported in 4.3% of patients, sustained elevations in 1.8%, and nonconsecutive elevations in 54.1% (Table 1) . Single occurrences of elevations .33 ULN were reported in 7.7% of patients for ALT and in 3.6% of patients for AST, and consecutive ALT elevations were seen in 1.9% of patients, sustained elevations in 0.02%, and nonconsecutive elevations in 4.0% of patients overall (Table 1) . Eight patients in the all-exposure population had an ALT or AST level .33 ULN and a total bilirubin level .23 ULN; all had additional underlying etiologies for the laboratory abnormalities and therefore did not meet the criteria for Hy's law according to independent adjudication (see Supplementary Table 3 , http://onlinelibrary.wiley. com/doi/10.1002/art.40176/abstract).
Early withdrawals from treatment as a result of elevated ALT/AST levels were reported as AEs by the investigator during routine monitoring (MedDRA AE terms included transaminases increased, ALT increased, hepatic enzyme increased, liver function test abnormal, transaminases abnormal, hypertransaminasemia, and AST increased); these occurred in 105 of 4,171 patients (2.5%; 107 events). Most withdrawals (77 of 105 patients [73.3%]) took place during the first 12 months of tocilizumab treatment.
We also analyzed the effect of tocilizumab treatment modification in patients with normal ALT/AST levels at baseline but with subsequent elevations .33 ) at baseline compared with 114 of 369 patients (30.9%) whose levels did normalize. The proportions of patients with other baseline variables, including age $65 years, diabetes mellitus, previous use of an anti-TNF agent, and concomitant use of DMARDs, were similar between those whose elevations normalized and those whose elevations did not ( Figure 3A) .
Comparison of ALT/AST elevations between patients receiving tocilizumab monotherapy and patients receiving tocilizumab combination therapy was not conducted on the all-exposure population because changes in and discontinuations of DMARDs were not strictly controlled during the long-term extension studies. Instead, data were used from the placebo-controlled population and the phase IV trial, as were 52-week data from the early RA trial, in which DMARD use was controlled. In these analyses, there was little difference between tocilizumab monotherapy and MTX monotherapy in the frequency or severity of ALT/AST elevations ( Table 2 ). For example, in patients from the early RA trial, ALT elevations from normal at baseline to .33 ULN occurred in 13 of 255 patients (5.1%) treated with placebo plus MTX and in 14 of 274 patients (5.1%) treated with tocilizumab monotherapy. The proportions of patients with elevations of ALT to .1-23 ULN and to .2-33 ULN were 32.5% and 8.2%, respectively, for the placebo plus MTX group and 32.5% and 5.5%, respectively, for the tocilizumab monotherapy group. Similar trends were seen in the tocilizumab monotherapy arms in the phase IV trial and the trial in MTXnaive and 6-month MTX-free patients. A numerically higher frequency of ALT/AST elevations was observed for patients treated with tocilizumab in combination with MTX/DMARDs than for those treated with MTX/ DMARDs alone (Table 2 ). For example, ALT elevations to .33 ULN ranged from 3.2% to 11.7% across the combination therapy populations and from 1.6% to 5.1% across the placebo plus MTX/DMARDs populations.
Hepatic AEs in patients treated with tocilizumab. In the all-exposure population, the overall rate of reported hepatic AEs was 0.78 per 100 patient-years (95% CI 0.65-0.93), which remained stable over time (see Supplementary Figure 1 , http://onlinelibrary.wiley. com/doi/10.1002/art.40176/abstract). Seven cases of hepatic SAEs were reported (overall rate 0.04 per 100 patient-years [95% CI 0.02-0.09]); events were variable, with no pattern over time (Table 3 ). None of the 149 patients receiving concomitant leflunomide experienced hepatic SAEs. No hepatic SAEs were reported during the placebo-controlled periods. 
DISCUSSION
This pooled analysis of patients in clinical trials receiving tocilizumab for a mean 6 SD of 3.9 6 2.0 years and a total exposure to tocilizumab of 16,204.8 patientyears demonstrated that mean ALT/AST levels increased early in tocilizumab treatment. Most elevations occurred within 12 months of tocilizumab initiation. Elevations were also reported in 12-month time periods Figure 3 . Baseline demographic characteristics and treatment modifications in patients with ALT/AST elevations .33 ULN that did or did not return to normal (A) and treatment modifications in patients with ALT/AST elevations .1-33 ULN that did or did not return to normal (B) (all-exposure population). Only patients with normal ALT and AST levels at baseline were included. Normalization was defined as a return of levels to #ULN. In patients with multiple ALT/AST elevations .33 ULN, assessment of ALT/AST normalization was made from the last recorded ALT/AST elevation .33 ULN only. BMI 5 body mass index; MTX 5 methotrexate; aTNF 5 anti-tumor necrosis factor; TCZ 5 tocilizumab; DMARD 5 disease-modifying antirheumatic drug (see Figure 1 for other definitions).
after the first year among patients who continued in the studies through month 84; however, the proportion with elevations did not increase with continued tocilizumab exposure during long-term treatment. In most patients, ALT/AST elevations were .1-23 ULN; elevations to .53 ULN occurred in 2.9% of patients for ALT and 0.9% of patients for AST. Most elevations .33 ULN were single occurrences, and levels in most patients who experienced ALT/AST elevations from normal to .33 ULN returned to normal (80%) or decreased to .1-23 ULN (15%).
Data from the pooled, placebo-controlled parts of the core phase III tocilizumab clinical trials and from additional phase III (early RA study) and phase IV trials that included tocilizumab monotherapy at 8 mg/kg demonstrated that the rates of ALT/AST elevations were similar between MTX monotherapy and tocilizumab monotherapy. Patients treated with the combination of tocilizumab and MTX/DMARDs had higher rates of ALT/AST elevations than those treated with MTX alone. Results from this analysis support the current liver enzyme monitoring guidelines, which recommend dose reduction of DMARDs followed by dose reduction or interruption of tocilizumab, with permanent discontinuation of tocilizumab in patients with elevations .53 ULN or persistent measurements $33 ULN (25, 26) .
A total of 7 hepatic SAEs (overall rate 0.04 per 100 patient-years [95% CI 0.02-0.09]) were observed in this analysis of patients with RA in tocilizumab clinical trials. The types of SAEs observed were variable, and all events occurred during the long-term extension periods of the trials, which were open-label and without a control arm (Table 3 ). Hepatic SAEs included 1 event each of hepatic cirrhosis, acute hepatic failure, ascites, hepatic steatosis, ischemic hepatitis, hepatitis, and autoimmune hepatitis. There was no pattern over time, and the relationship to tocilizumab treatment (as determined by the investigator) was variable. Liver biopsy was optional in these studies and was not performed in some patients with persistent elevations, which might have led to fewer reported events.
Rates of hepatic SAEs have not been broadly reported for RA patients in the age of biologic agents, and published data are limited. Similar analyses of hepatic SAEs in clinical trials have not been published; therefore, it is unknown at this time whether the rate reported herein for tocilizumab clinical trials is typical for patients with RA treated with other agents over long-term periods. Rates of SAEs derived from clinical trials of tocilizumab should not be directly compared with rates derived from epidemiologic data because of the regional differences, the differences in data collection methodologies in controlled trials compared with claims and registry databases, and the different patient populations. Table 3 . Details of hepatic serious AEs (tocilizumab all-exposure population)*
Hepatic cirrhosis
A 58-year-old woman with RA of 7 months' duration at baseline was diagnosed as having cholelithiasis and underwent cholecystectomy 44 days after her last dose of tocilizumab; she had been taking tocilizumab for 4.4 years The patient had nonconsecutive ALT/AST elevations ,23 ULN during the first 1.5 years of the study; in the subsequent 2.8 years, ALT levels were normal; AST levels were elevated .1-1.53 ULN; ALT and AST levels were 1.23 ULN and 1.83 ULN, respectively, on the day of her last tocilizumab dose Liver biopsy revealed evidence of cirrhosis in evolution, grade 5 fibrosis, and severe microvesicular and macrovesicular steatosis; the investigator reported that the patient had no symptoms related to cirrhosis The patient was receiving concomitant MTX; no relevant medical history was reported Tocilizumab was discontinued, and the event was unresolved at last contact Worsening autoimmune hepatitis
A 59-year-old woman with RA of 10 years' duration at baseline and a history of autoimmune hepatitis experienced worsening of autoimmune hepatitis after taking tocilizumab for 1.2 years ALT and AST levels were 1.53 ULN and 1.73 ULN, respectively, at baseline and remained persistently elevated throughout the study; ALT ranged from 1.3 to 4.23 ULN, and AST ranged from .1 to 3.53 ULN; ALT and AST levels were 3.63 ULN and 3.13 ULN, respectively, 65 days before the event and 3.13 ULN and 2.03 ULN, respectively, on the day of the event; the patient had a 10-year history of elevated hepatic enzyme levels before study entry Liver biopsy revealed evidence of autoimmune hepatitis with moderate lymphoplasmacytic inflammatory activity, moderate necrosis, bile duct proliferation, and portal and periportal fibrosis with extensive portal bridging; extensive, mostly macrovesicular, steatosis was evident The patient was receiving concomitant MTX and prednisone and had previously been treated with leflunomide; she had a history of autoimmune hepatitis and hypertension Tocilizumab was discontinued, and treatment with azathioprine and higher steroid dose was commenced; the event was unresolved at last contact Acute hepatic failure
A 59-year-old woman with RA of 10 months' duration at baseline experienced acute hepatic failure from portal vein and hepatic vein thromboses and then fatal liver and renal failure after taking tocilizumab for 3.7 years Liver function test results were normal during tocilizumab treatment before the event The patient was receiving concomitant MTX and prednisone, had a history of positive findings on anticardiolipin antibody testing for immunoglobulin G, and was a smoker Ascites of unknown etiology
A 73-year-old woman with RA of 16 years' duration at baseline underwent extensive evaluation with differential diagnoses after experiencing nausea and general malaise; her final diagnosis was ascites of unknown etiology and acute renal failure The patient's ALT and AST levels were normal during the first 2 years of the study; in the 7 months before the event, the ALT level ranged from 1.3 to 2.33 ULN and the AST level ranged from 13 ULN to 1.13 ULN The patient was receiving concomitant MTX and had a history of hypertension The tocilizumab dose was interrupted, and symptoms resolved spontaneously without sequelae Ischemic hepatitis due to anaphylaxis
A 53-year-old woman with RA of 18 years' duration at baseline developed acute allergic reaction to tocilizumab and ischemic hepatitis secondary to hypotension after taking tocilizumab for 1.2 years ALT levels were frequently .ULN in the study for 1.2 years before the event (maximum 2.63 ULN); the AST level ranged from 13 ULN to 1.83 ULN; at the time of the event, AST and ALT levels were 343 ULN and 153 ULN, respectively The patient was receiving concomitant methylprednisolone and had a history of hypertension Tocilizumab was discontinued, and the event resolved without sequelae Hepatic steatosis
A 62-year-old woman with RA of 31 years' duration at baseline had elevated liver enzyme levels and was diagnosed as having hepatic steatosis after taking tocilizumab for 1.7 years ALT and AST levels were persistently 1.23 ULN and 13 ULN, respectively, during the study and 13 ULN and 1.83 ULN, respectively, on the day of the event Liver biopsy confirmed major macrovacuolar steatosis, in combination with minimal portal and periportal fibrosis and a portal and interlobular inflammatory infiltrate that was nonspecific in appearance; no hepatocyte swelling or hepatocyte necrosis was observed The patient had a history of hypertension Tocilizumab was discontinued, and liver enzyme levels normalized; the event was unresolved at last contact Hepatitis A 45-year-old woman with RA of 1 year's duration at baseline was diagnosed as having hepatitis and elevated transaminase levels after taking tocilizumab for 4.3 years During the 4.6 years before the event, the patient had sporadic ALT elevations 1.1-1.63 ULN; AST levels remained normal throughout the study, except for one elevation 1.73 ULN associated with an AE of acute gastroenteritis. ALT and AST levels were 5.93 ULN and 8.43 ULN, respectively, on the day of the event The patient was receiving concomitant MTX and prednisone and had a history of hypertension Tocilizumab was discontinued ;2 months before the event, and the event resolved without sequelae * AEs 5 adverse events; RA 5 rheumatoid arthritis; AST 5 aspartate aminotransferase; ALT 5 alanine aminotransferase; ULN 5 upper limit of normal; MTX 5 methotrexate.
POOLED LONG-TERM ANALYSIS OF LIVER SAFETY WITH TOCILIZUMAB TREATMENT FOR RA
Overall, the data from clinical trials of intravenous tocilizumab suggest that the observed elevations in transaminase levels did not result in an increased rate of hepatic SAEs during the interval described. Data from clinical trials of subcutaneous tocilizumab were not included in the current analysis. Published clinical trials show ALT/AST elevations .ULN in 50.6%/37.9% of patients receiving subcutaneous tocilizumab and in 44.1%/35.3% of patients receiving intravenous tocilizumab (28) . Assessing the risk of hepatic diseases with biologic treatments is an evolving field and may require even longer-term data. It should be noted that these results were observed in the clinical trial setting, where patients with important comorbidities, such as history of or current hepatic disease, were not enrolled, where frequent monitoring of laboratory measures was mandatory, and where recommendations and mitigation strategies for patients with elevations in liver transaminases were prespecified. Furthermore, patients with ALT/AST elevations .53 ULN or persistent elevations $33 ULN permanently discontinued tocilizumab, and thus at-risk patients were excluded from further analysis.
This highlights the importance of monitoring patients in clinical practice. Further long-term observations of real-world data will be needed to determine whether the elevations in liver transaminase levels reported in patients treated with tocilizumab could eventually lead to clinically significant hepatic disease. For the present, we advocate regular monitoring of transaminase enzyme levels (25, 26) , with adjustment of the dose of either tocilizumab or a concomitant DMARD such as MTX or leflunomide in the event of persistent elevations of hepatic enzyme levels into the abnormal range.
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